Kiora Pharmaceuticals, Inc. ((KPRX)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Study Overview: Kiora Pharmaceuticals, Inc. is conducting a Phase 2 study titled ‘Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema (KLARITY-1).’ The study aims to evaluate the safety, tolerability, and efficacy of KIO-104, a novel treatment for macular edema, highlighting its potential significance in addressing this condition.
Intervention/Treatment: The study tests KIO-104, an ophthalmic formulation for intravitreal injection. It is a non-steroidal, small molecule inhibitor targeting dihydroorotate dehydrogenase (DHODH), designed to treat macular edema.
Study Design: This interventional study is open-label and non-randomized, employing a parallel intervention model. Participants receive either low or high doses of KIO-104 at two- or four-week intervals, with the primary aim of treatment. No masking is involved in this study.
Study Timeline: The study began on February 4, 2025, with the latest update submitted on July 31, 2025. These dates are crucial as they mark the progress and current status of the study, which is still recruiting participants.
Market Implications: The ongoing study of KIO-104 could potentially enhance Kiora Pharmaceuticals’ market position if successful, offering a new treatment option for macular edema. This development may influence investor sentiment positively, especially if the drug shows promising results compared to existing treatments in the market.
The study is ongoing, with further details available on the ClinicalTrials portal.